A meta-analysis of clinical studies from 2010 to 2019 revealed that ARNI exerted reverse remodelling in terms of reduced LV size and hypertrophy compared with ACE inhibitors or AT1R blockers in patients with HF with a reduced LV ejection fraction [35]. Here, AGTR1 is linked to hypertrophy.